Airsupra (PT027) approved in the US for asthma
First and only rescue medication approved in the US for as-needed use to reduce risk of asthma exacerbations.Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. The approval by the Food and Drug Administration (FDA) was based on results from the MANDALA and DENALI Phase III trials.[1,2] In MANDALA, Airsupra significantly reduced the risk of severe exacerbations compared to albuterol in patients with